Russian billionaire to acquire control of Veropharm
Roman Avdeev, a well-known Russian banker and one of the country’s richest people, has agreed to acquire a controlling (52%) stake in Veropharm, one of Russia’s leading generic and branded drugmakers from its current owner 36.6, one of Russia’s leading pharmacy chains.
The amount of the deal is estimated at 5 billion roubles ($150 million). According to Mr Avdeev, Veropharm is a promising asset, which has big potential for further growth.
He has also added that currently he has no plans to change the current strategy of Veropharm’s development and plans to continue implementation of the company’s investment program, which was approved by its previous management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze